Literature DB >> 32461687

Introducing PIONEER: a project to harness big data in prostate cancer research.

Muhammad Imran Omar1, Monique J Roobol2, Maria J Ribal3, Thomas Abbott4, Paul-Michael Agapow5, Sonia Araujo6, Alex Asiimwe7, Charles Auffray8, Irina Balaur8, Katharina Beyer9, Chiara Bernini10, Anders Bjartell11, Alberto Briganti12, John-Edward Butler-Ransohoff7, Riccardo Campi3, Marinel Cavelaars13, Bertrand De Meulder8, Zsuzsanna Devecseri14, Marc Dietrich Voss14, Konstantinos Dimitropoulos3, Susan Evans-Axelsson11, Billy Franks4, Louise Fullwood15, Denis Horgan10, Emma Jane Smith3, Amit Kiran4, Kati Kivinummi16, Mark Lambrecht17, Doron Lancet18, Peter Lindgren19, Sara MacLennan20, Steven MacLennan20, Maria Manuela Nogueira8, Fredrik Moen19, Maxim Moinat13, Kishore Papineni4, Christian Reich6, Kristin Reiche21, Stijn Rogiers17, Claudio Sartini7, Kees van Bochove13, Femke van Diggelen22, Mieke Van Hemelrijck9, Hein Van Poppel3, Jihong Zong7, James N'Dow3.   

Abstract

Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.

Entities:  

Mesh:

Year:  2020        PMID: 32461687     DOI: 10.1038/s41585-020-0324-x

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  2 in total

1.  Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary.

Authors:  Scott E Eggener; R Bryan Rumble; Himisha Beltran
Journal:  JCO Oncol Pract       Date:  2020-01-28

2.  tranSMART: An Open Source Knowledge Management and High Content Data Analytics Platform.

Authors:  Elisabeth Scheufele; Dina Aronzon; Robert Coopersmith; Michael T McDuffie; Manish Kapoor; Christopher A Uhrich; Jean E Avitabile; Jinlei Liu; Dan Housman; Matvey B Palchuk
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2014-04-07
  2 in total
  4 in total

1.  MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression.

Authors:  Po Xu; Ying Wang; Zhe Deng; Zhibo Tan; Xiaojuan Pei
Journal:  Oncol Lett       Date:  2022-01-03       Impact factor: 2.967

2.  The need for core outcome sets in urological cancer research.

Authors:  Steven MacLennan; Paula R Williamson
Journal:  Transl Androl Urol       Date:  2021-06

Review 3.  Contemporary application of artificial intelligence in prostate cancer: an i-TRUE study.

Authors:  B M Zeeshan Hameed; Milap Shah; Nithesh Naik; Sufyan Ibrahim; Bhaskar Somani; Patrick Rice; Naeem Soomro; Bhavan Prasad Rai
Journal:  Ther Adv Urol       Date:  2021-01-23

Review 4.  OMOP CDM Can Facilitate Data-Driven Studies for Cancer Prediction: A Systematic Review.

Authors:  Najia Ahmadi; Yuan Peng; Markus Wolfien; Michéle Zoch; Martin Sedlmayr
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.